PMID- 34877460
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2513-9878 (Electronic)
IS  - 2513-9878 (Linking)
VI  - 3
IP  - 1
DP  - 2021
TI  - The effect on tumour control probability of using AXB algorithm in replacement of 
      AAA for SBRT of hepatocellular carcinoma located at lung-liver boundary region.
PG  - 20210041
LID - 10.1259/bjro.20210041 [doi]
LID - 20210041
AB  - OBJECTIVE: To retrospectively analyze the clinical impact on stereotactic body 
      radiation therapy (SBRT) for hepatocellular carcinoma (HCC) located at lung-liver 
      boundary due to the use of Acuros XB algorithm (AXB) in replacement of 
      anisotropic analytical algorithm (AAA). METHODS: 23 SBRT volumetric modulated arc 
      therapy (VMAT) plans for HCC located at lung-liver boundary were calculated using 
      AAA and AXB respectively with the same treatment parameters. The dose-volume data 
      of the planned target volumes (PTVs) were compared. A published tumour control 
      probability (TCP) model was used to calculate the effect of dosimetric difference 
      between AAA and AXB on tumour control probability. RESULTS: For dose calculated 
      by AXB (Dose to medium), the D95% and D98% of the PTV were on average 2.4 and 
      3.1% less than that calculated by AAA. For dose calculated by AXB (dose to 
      water), the D95% and D98% of the PTV were on average 1.8%, and 2.7% less than 
      that calculated by AAA. Up to 5% difference in D95% and 8% difference in D98% 
      were observed in the worst cases. The significant decrease in D95% calculated by 
      AXB compared to AAA could result in a % decrease in 2 year TCP up to 8% in the 
      worst case (from 46.8 to 42.9%). CONCLUSION: The difference in dose calculated by 
      AAA and AXB could lead to significant difference in TCP for HCC SBRT located at 
      lung-liver boundary region. ADVANCES IN KNOWLEDGE: The difference in calculated 
      dose and tumour control probability for HCC SBRT between AAA and AXB algorithm at 
      lung-liver boundary region was compared.
CI  - (c) 2021 The Authors. Published by the British Institute of Radiology.
FAU - Cheung, Michael Lok Man
AU  - Cheung MLM
FAU - Kan, Monica Wk
AU  - Kan MW
FAU - Yeung, Vanessa Ty
AU  - Yeung VT
FAU - Poon, Darren Mc
AU  - Poon DM
AD  - State Key Laboratory of Translational Oncology, The Chinese University of Hong 
      Kong, Hong Kong, SAR, China.
FAU - Kam, Michael Km
AU  - Kam MK
AD  - State Key Laboratory of Translational Oncology, The Chinese University of Hong 
      Kong, Hong Kong, SAR, China.
FAU - Lee, Louis Ky
AU  - Lee LK
AD  - State Key Laboratory of Translational Oncology, The Chinese University of Hong 
      Kong, Hong Kong, SAR, China.
FAU - Chan, Anthony Tc
AU  - Chan AT
LA  - eng
PT  - Journal Article
DEP - 20211124
PL  - England
TA  - BJR Open
JT  - BJR open
JID - 101749810
PMC - PMC8611685
EDAT- 2021/12/09 06:00
MHDA- 2021/12/09 06:01
PMCR- 2021/10/18
CRDT- 2021/12/08 06:34
PHST- 2021/06/21 00:00 [received]
PHST- 2021/09/16 00:00 [revised]
PHST- 2021/09/30 00:00 [accepted]
PHST- 2021/12/08 06:34 [entrez]
PHST- 2021/12/09 06:00 [pubmed]
PHST- 2021/12/09 06:01 [medline]
PHST- 2021/10/18 00:00 [pmc-release]
AID - 10.1259/bjro.20210041 [doi]
PST - epublish
SO  - BJR Open. 2021 Nov 24;3(1):20210041. doi: 10.1259/bjro.20210041. eCollection 
      2021.